trending Market Intelligence /marketintelligence/en/news-insights/trending/uyoq0iceryjn6xuqbozv8w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioMarin's application for genetic disease drug accepted by EMA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

BioMarin's application for genetic disease drug accepted by EMA

BioMarin Pharmaceutical Inc. said the European Medicines Agency accepted the company's marketing authorization application for pegvaliase to treat the genetic disorder phenylketonuria.

Phenylketonuria is an inherited disorder that increases the levels of phenylalanine, an amino acid, in the blood.

The San Rafael, Calif.-based biotechnology company seeks approval of the drug to reduce blood phenylalanine levels in patients with phenylketonuria whose phenylalanine levels are not adequately controlled with existing treatment options such as sapropterin.

In December 2017, the U.S. Food and Drug Administration extended the review period of the company's application for pegvaliase.